Collagen Solutions plc Annual report and accounts 2017 Core business growth  
development, supply and manufacturing business as well as our new proprietary products to take advantage of the high-growth 
The Group’s results for the year ended 31 March 2017 are set out in 
+£10.8m During the year the team delivered nine new supply, development 
The long-term success of the Group depends on the continual review, assessment and control of the key business risks it faces.
financial statements for the year ended 31 March 2017 and up 
directors believe that the Group is well placed to manage its business 
Pension payments of £13,683 were made on behalf of the directors to the Company’s various money purchase schemes in the year 
At 31 March 2017, the following directors held options over the shares of the Company:
The trading results for the year and the Group’s financial position 
There are 500,000 deferred shares of 9p in issue at 31 March 2017 and directors’ interests are held as follows: David Evans – 125,000 
shares are required to be issued by the Company under the asset 
the Company and the financial performance of the Group.
In preparing the Group and Company financial statements, 
Directors’ report continued 27 Annual report and accounts 2017 Collagen Solutions plc
FINANCIAL STATEMENTS 28 Collagen Solutions plc Annual report and accounts 2017
We have audited the group and parent company financial 
for the year ended 31 March 2017 30 Collagen Solutions plc Annual report and accounts 2017
Company number: 8446337 32 Collagen Solutions plc Annual report and accounts 2017
for the year ended 31 March 2017 FINANCIAL STATEMENTS
for the year ended 31 March 2017 FINANCIAL STATEMENTS
Cash and cash equivalents at the end of the financial year 7,776,079 1,321,938 36 Collagen Solutions plc Annual report and accounts 2017
The financial statements of Collagen Solutions plc and its subsidiaries (the “Group”) for the year ended 31 March 2017 were authorised 
and in accordance with those parts of the Companies Act 2006 applicable to companies reporting under IFRSs. The financial statements have been prepared on the historical cost basis except for certain financial liabilities incorporated at fair value.
of a subsidiary is the fair values of the assets transferred, the liabilities incurred and the equity interests issued by the Group.
basis of preparing the financial statements, the directors are required to consider whether the Company can continue in operational 
As at 31 March 2017 the Group had cash and cash equivalents of £8.98 million and net current assets of £7.95 million.
relevant and appropriate enquiries, including consideration of the Company’s and the Group’s current cash resources and the working 
capital forecasts, the directors have a reasonable expectation that the Company and the Group will have adequate cash resources to 
The Group receives government grants in relation to research and development, business development and employment costs.
The Group issues equity-settled share-based payment transactions to certain employees, directors and suppliers.
value of the parent company’s investment in the subsidiaries and is credited to the share-based payment reserve.
The following standards have been adopted by the Group for the first time for the financial year beginning on or after 1 April 2016 
The average number of staff employed by the Group, including directors, during the financial year amounted to:
During the years ended 31 March 2017 and 31 March 2016, Collagen Solutions (UK) Limited created and surrendered tax losses under 
management’s plans to cross-sell the Group’s expanded range of current and pipeline products into existing customers and markets, 
The amounts recognised as of the date of relevant acquisitions are as follows: Collagen Solutions (UK) Limited – £1,782,122; 
The terms for Collagen Solutions (UK) Limited required the Group to pay the vendors two tranches of up to £1 million in ordinary 
shares based on a 12.5p strike price, i.e. 8 million ordinary shares dependent on Group turnover reaching £2.25 million and securing 
During the year ended 31 March 2017, both tranches of 8 million ordinary shares were issued 
The Group and the Company have not utilised forward contracts to hedge future purchase transactions and cash flows in the financial year.
Credit risk with respect to trade receivables is due to the Group and Company trading with a limited number of companies which are 
The Group’s and the Company’s maximum exposure to credit risk is reflected in the carrying amounts of their financial assets as set out 
The Group and Company manage liquidity risk to ensure that they will have sufficient liquidity to meet their liabilities as they fall due.
The Group’s and the Company’s financial assets at 31 March 2017 comprised cash and trade receivables.
£8,978,150 (2016: £2,493,146) (Group) and £7,776,079 (2016: £1,321,938) (Company) are floating rate financial assets.
The fair values based upon the market value or discounted cash flows of financial liabilities and financial assets held in the Group 
The Company has granted equity-settled share options to seven employees, three of whom are directors.
The Group recognised the following expense in relation to share-based payment transactions:
Non-executive directors charged the Company the following consultancy fees during the year ended 31 March 2017: David Evans 
The Company received £8,000 (2016: £5,000) from Taragenyx Limited in relation to services provided by director Stewart White who 
A further 217,475 ordinary shares are required to be issued by the Company under the asset purchase 
This reserve is the result of the Company’s grant of equity-settled share options to selected employees and is measured in accordance 
This reserve arises from the premium on the difference between the fair value share price of Collagen Solutions plc shares issued as 
to satisfy part of the consideration in the acquisition of Collagen Solutions (UK) Limited, the acquisition of the business and assets 
1.  To receive and adopt the Company’s accounts for the financial year ended 31 March 2017, together with the Directors’ Report 
The Company is required to appoint auditors for each financial year of the Company.
of RSM UK Audit LLP as the Company’s auditors for the current financial year of the Company ending on 31 March 2018.